Targeting pro-inflammatory cytokines following joint injury: Acute intra-articular inhibition of interleukin-1 following knee injury prevents post-traumatic arthritis

Arthritis Research and Therapy

Volumn 16, Issue 3, 2014, Pages

  Furman, Bridgette D ^a   Mangiapani, Daniel S ^a   Zeitler, Evan ^a   Bailey, Karsyn N ^a   Horne, Phillip H ^a   Huebner, Janet L ^a   Kraus, Virginia B ^a   Guilak, Farshid ^a   Olson, Steven A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE RECEPTOR ANTAGONIST; ETANERCEPT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; AUTACOID; IMMUNOGLOBULIN G; INTERLEUKIN 1; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE DEGENERATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG MECHANISM; HISTOLOGY; INTRAARTICULAR FRACTURE; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSMOTIC PUMP; POSTTRAUMATIC ARTHROPATHY; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; SYNOVITIS; SYSTEMIC THERAPY; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, EXPERIMENTAL; BLOOD; C57BL MOUSE; COMPLICATION; DRUG EFFECTS; FRACTURE; INTRAARTICULAR DRUG ADMINISTRATION; KNEE; KNEE INJURIES; METABOLISM; PATHOLOGY; TREATMENT OUTCOME; ANIMAL TISSUE; BONE DENSITY; BONE MASS; BONE METABOLISM; COMPARATIVE STUDY; COMPUTED TOMOGRAPHY SCANNER; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMUR CONDYLE; FIBROCARTILAGE; INFLAMMATION; KNEE FRACTURE; KNEE INJURY; LOCAL THERAPY; METAPHYSIS; PROTEIN BLOOD LEVEL; SYNOVIAL FLUID LEVEL; TRABECULAR BONE;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; FRACTURES, CLOSED; IMMUNOGLOBULIN G; INFLAMMATION MEDIATORS; INJECTIONS, INTRA-ARTICULAR; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; INTRA-ARTICULAR FRACTURES; KNEE INJURIES; KNEE JOINT; MALE; MICE, INBRED C57BL; RECEPTORS, TUMOR NECROSIS FACTOR; SYNOVITIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; X-RAY MICROTOMOGRAPHY;

EID: 84902937378     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4591     Document Type: Article

References (78)

1. Brown TD, Johnston RC, Saltzman CL, Marsh JL, Buckwalter JA. Posttraumatic osteoarthritis: a first estimate of incidence, prevalence, and burden of disease. J Orthop Trauma 2006, 20:739-744. 10.1097/01.bot.0000246468.80635.ef, 17106388.
2. Swiontkowski MF, Chapman JR. Cost and effectiveness issues in care of injured patients. Clin Orthop Relat Res 1995, 318:17-24.
3. Cross JD, Ficke JR, Hsu JR, Masini BD, Wenke JC. Battlefield orthopaedic injuries cause the majority of long-term disabilities. J Am Acad Orthop Surg 2011, 19:S1-S7.
4. Lohmander LS, Englund PM, Dahl LL, Roos EM. The long-term consequence of anterior cruciate ligament and meniscus injuries: osteoarthritis. Am J Sports Med 2007, 35:1756-1769. 10.1177/0363546507307396, 17761605.
5. Roos H, Lauren M, Adalberth T, Roos EM, Jonsson K, Lohmander LS. Knee osteoarthritis after meniscectomy: prevalence of radiographic changes after twenty-one years, compared with matched controls. Arthritis Rheum 1998, 41:687-693. 10.1002/1529-0131(199804)41:4<687::AID-ART16>3.0.CO;2-2, 9550478.
6. Christoforakis J, Pradhan R, Sanchez-Ballester J, Hunt N, Strachan RK. Is there an association between articular cartilage changes and degenerative meniscus tears?. Arthroscopy 2005, 21:1366-1369. 10.1016/j.arthro.2005.08.031, 16325089.
7. Bretlau T, Tuxoe J, Larsen L, Jorgensen U, Thomsen HS, Lausten GS. Bone bruise in the acutely injured knee. Knee Surg Sports Traumatol Arthrosc 2002, 10:96-101. 10.1007/s00167-001-0272-9, 11914767.
8. Chu CR, Williams A, Tolliver D, Kwoh CK, Bruno S, Irrgang JJ. Clinical optical coherence tomography of early articular cartilage degeneration in patients with degenerative meniscal tears. Arthritis Rheum 2010, 62:1412-1420. 10.1002/art.27378, 2972585, 20213801.
9. Furman BD, Olson SA, Guilak F. The development of posttraumatic arthritis after articular fracture. J Orthop Trauma 2006, 20:719-725. 10.1097/01.bot.0000211160.05864.14, 17106385.
10. Olson SA, Marsh JL. Posttraumatic osteoarthritis. Clin Orthop Relat Res 2004, 423:2.
11. Matta JM. Fractures of the acetabulum: accuracy of reduction and clinical results in patients managed operatively within three weeks after the injury. J Bone Joint Surg Am Vol 1996, 78:1632-1645.
12. Irie K, Uchiyama E, Iwaso H. Intraarticular inflammatory cytokines in acute anterior cruciate ligament injured knee. Knee 2003, 10:93-96. 10.1016/S0968-0160(02)00083-2, 12649034.
13. Swärd P, Frobell R, Englund M, Roos H, Struglics A. Cartilage and bone markers and inflammatory cytokines are increased in synovial fluid in the acute phase of knee injury (hemarthrosis)-a cross-sectional analysis. Osteoarthritis Cartilage 2012, 20:1302-1308. 10.1016/j.joca.2012.07.021, 22874525.
14. Bigoni M, Sacerdote P, Turati M, Franchi S, Gandolla M, Gaddi D, Moretti S, Munegato D, Augusti CA, Bresciani E, Omeljaniuk RJ, Locatelli V, Torsello A. Acute and late changes in intraarticular cytokine levels following anterior cruciate ligament injury. J Orthop Res 2013, 31:315-321. 10.1002/jor.22208, 22886741.
15. Lewis JS, Hembree WC, Furman BD, Tippets L, Cattel D, Huebner JL, Little D, DeFrate LE, Kraus VB, Guilak F, Olson SA. Acute joint pathology and synovial inflammation is associated with increased intra-articular fracture severity in the mouse knee. Osteoarthritis Cartilage 2011, 19:864-873. 10.1016/j.joca.2011.04.011, 3312469, 21619936.
16. Cameron M, Buchgraber A, Passler H, Vogt M, Thonar E, Fu F, Evans CH. The natural history of the anterior cruciate ligament-deficient knee. Changes in synovial fluid cytokine and keratan sulfate concentrations. Am J Sports Med 1997, 25:751-754. 10.1177/036354659702500605, 9397261.
17. Marks PH, Donaldson ML. Inflammatory cytokine profiles associated with chondral damage in the anterior cruciate ligament-deficient knee. Arthroscopy 2005, 21:1342-1347. 10.1016/j.arthro.2005.08.034, 16325085.
18. Elsaid KA, Fleming BC, Oksendahl HL, Machan JT, Fadale PD, Hulstyn MJ, Shalvoy R, Jay GD. Decreased lubricin concentrations and markers of joint inflammation in the synovial fluid of patients with anterior cruciate ligament injury. Arthritis Rheum 2008, 58:1707-1715. 10.1002/art.23495, 2789974, 18512776.
19. Ward BD, Furman BD, Huebner JL, Kraus VB, Guilak F, Olson SA. Absence of posttraumatic arthritis following intraarticular fracture in the MRL/MpJ mouse. Arthritis Rheum 2008, 58:744-753. 10.1002/art.23288, 18311808.
20. Goldring MB. Osteoarthritis and cartilage: the role of cytokines. Curr Rheumatol Rep 2000, 2:459-465. 10.1007/s11926-000-0021-y, 11123098.
21. Fernandes J, Martel-Pelletier J, Pelletier J. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002, 39:237.
22. Catterall JB, Stabler TV, Flannery CR, Kraus VB. Changes in serum and synovial fluid biomarkers after acute injury (NCT00332254). Arthritis Res Ther 2010, 12:R229. 10.1186/ar3216, 3046542, 21194441.
23. Lindhorst E, Vail TP, Guilak F, Wang H, Setton LA, Vilim V, Kraus VB. Longitudinal characterization of synovial fluid biomarkers in the canine meniscectomy model of osteoarthritis. J Orthop Res 2000, 18:269-280. 10.1002/jor.1100180216, 10815829.
24. Kramer WC, Hendricks KJ, Wang J. Pathogenetic mechanisms of posttraumatic osteoarthritis: opportunities for early intervention. Int J Clin Exp Med 2011, 4:285-298. 3228584, 22140600.
25. Furman BD, Strand J, Hembree WC, Ward BD, Guilak F, Olson SA. Joint degeneration following closed intraarticular fracture in the mouse knee: a model of posttraumatic arthritis. J Orthop Res 2007, 25:578-592. 10.1002/jor.20331, 17266145.
26. Lewis JS, Furman BD, Zeitler E, Huebner JL, Kraus VB, Guilak F, Olson SA. Genetic and cellular evidence of decreased inflammation associated with reduced incidence of posttraumatic arthritis in MRL/MpJ mice. Arthritis Rheum 2013, 65:660-670. 10.1002/art.37796, 3721663, 23203659.
27. Eisenberg SP, Evans RJ, Arend WP, Verderber E, Brewer MT, Hannum CH, Thompson RC. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990, 343:341-346. 10.1038/343341a0, 2137201.
28. Bakker AC, Joosten LA, Arntz OJ, Helsen MM, Bendele AM, van de Loo FA, van den Berg WB. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum 1997, 40:893-900. 10.1002/art.1780400517, 9153551.
29. Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992, 77:510-514. 1421669, 1337334.
30. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 1992, 89:7375-7379. 10.1073/pnas.89.16.7375, 49712, 1502148.
31. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992, 89:9784-9788. 10.1073/pnas.89.20.9784, 50217, 1409699.
32. McNulty AL, Moutos FT, Weinberg JB, Guilak F. Enhanced integrative repair of the porcine meniscus in vitro by inhibition of interleukin-1 or tumor necrosis factor alpha. Arthritis Rheum 2007, 56:3033-3042. 10.1002/art.22839, 17729298.
33. Beamer WG, Donahue LR, Rosen CJ, Baylink DJ. Genetic variability in adult bone density among inbred strains of mice. Bone 1996, 18:397-403. 10.1016/8756-3282(96)00047-6, 8739896.
34. Sheng MH, Baylink DJ, Beamer WG, Donahue LR, Rosen CJ, Lau KH, Wergedal JE. Histomorphometric studies show that bone formation and bone mineral apposition rates are greater in C3H/HeJ (high-density) than C57BL/6 J (low-density) mice during growth. Bone 1999, 25:421-429. 10.1016/S8756-3282(99)00184-2, 10511108.
35. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 1996, 39:797-809. 10.1002/art.1780390513, 8639177.
36. van de Loo FA, Joosten LA, van Lent PL, Arntz OJ, van den Berg WB. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995, 38:164-172. 10.1002/art.1780380204, 7848306.
37. Knedla A, Riepl B, Lefevre S, Kistella S, Grifka J, Straub RH, Gay S, Scholmerich J, Muller-Ladner U, Neumann E. The therapeutic use of osmotic minipumps in the severe combined immunodeficiency (SCID) mouse model for rheumatoid arthritis. Ann Rheum Dis 2009, 68:124-129.
38. Quattrocchi E, Walmsley M, Browne K, Williams RO, Marinova-Mutafchieva L, Buurman W, Butler DM, Feldmann M. Paradoxical effects of adenovirus-mediated blockade of TNF activity in murine collagen-induced arthritis. J Immunol 1999, 163:1000-1009.
39. Bloquel C, Bessis N, Boissier MC, Scherman D, Bigey P. Gene therapy of collagen-induced arthritis by electrotransfer of human tumor necrosis factor-alpha soluble receptor I variants. Hum Gene Ther 2004, 15:189-201. 10.1089/104303404772679995, 14975191.
40. Bendele A, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis Rheum 1999, 42:498-506. 10.1002/1529-0131(199904)42:3<498::AID-ANR15>3.0.CO;2-A, 10088773.
41. Inoue K, Masuko-Hongo K, Okamoto M, Nishioka K. Efficacy of daily compared to intermittent administration of IL-1Ra for protection against bone and cartilage destruction in collagen-challenged mice. Clin Exp Rheumatol 2003, 21:33-39.
42. Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, Dunstan C, Kollias G, Steiner G, Smolen J, Schett G. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004, 50:277-290. 10.1002/art.11487, 14730626.
43. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor-necrosis-factor receptor fc fusion protein on type-ii collagen-induced arthritis in mice. J Immunol 1993, 151:6602-6607.
44. Williams RO, Ghrayeb J, Feldmann M, Maini RN. Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 1995, 84:433-439. 1415129, 7751027.
45. Geboes L, De Klerck B, Van Balen M, Kelchtermans H, Mitera T, Boon L, De Wolf-Peeters C, Matthys P. Freund's complete adjuvant induces arthritis in mice lacking a functional interferon-gamma receptor by triggering tumor necrosis factor alpha-driven osteoclastogenesis. Arthritis Rheum 2007, 56:2595-2607. 10.1002/art.22791, 17665444.
46. Seifer DR, Furman BD, Guilak F, Olson SA, Brooks SC, Kraus VB. Novel synovial fluid recovery method allows for quantification of a marker of arthritis in mice. Osteoarthritis Cartilage 2008, 16:1532-1538. 10.1016/j.joca.2008.04.013, 2602808, 18538588.
47. Hildebrand T, Ruegsegger P. Quantification of bone microarchitecture with the structure model index. Comput Methods Biomech Biomed Engin 1997, 1:15-23. 10.1080/01495739708936692, 11264794.
48. Waarsing JH, Day JS, Weinans H. An improved segmentation method for in vivo microCT imaging. J Bone Miner Res 2004, 19:1640-1650. 10.1359/JBMR.040705, 15355559.
49. Mankin HJ, Johnson ME, Lippiello L. Biochemical and metabolic abnormalities in articular cartilage from osteoarthritic human hips. III. Distribution and metabolism of amino sugar-containing macromolecules. J Bone Joint Surg Am 1981, 63:131-139.
50. Carlson CS, Guilak F, Vail TP, Gardin JF, Kraus VB. Synovial fluid biomarker levels predict articular cartilage damage following complete medial meniscectomy in the canine knee. J Orthop Res 2002, 20:92-100. 10.1016/S0736-0266(01)00066-3, 11853096.
51. Krenn V, Morawietz L, Burmester GR, Kinne RW, Mueller-Ladner U, Muller B, Haupl T. Synovitis score: discrimination between chronic low-grade and high-grade synovitis. Histopathology 2006, 49:358-364. 10.1111/j.1365-2559.2006.02508.x, 16978198.
52. Immunex-Corporation, Amgen Canada Product Monograph Enbrel - etanercept. Regulatory Affairs of Canada 2012, [http://www.amgen.ca/Enbrel_PM.pdf], Immunex-Corporation, Amgen Canada.
53. Kraus VB, Birmingham J, Stabler TV, Feng S, Taylor DC, Moorman CT, Garrett WE, Toth AP. Effects of intraarticular IL1-Ra for acute anterior cruciate ligament knee injury: a randomized controlled pilot trial (NCT00332254). Osteoarthritis Cartilage 2012, 20:271-278. 10.1016/j.joca.2011.12.009, 22273632.
54. Cohen SB, Proudman S, Kivitz AJ, Burch FX, Donohue JP, Burstein D, Sun YN, Banfield C, Vincent MS, Ni L, Zack DJ. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res Ther 2011, 13:R125. 10.1186/ar3430, 3239365, 21801403.
55. Chevalier X, Goupille P, Beaulieu AD, Burch FX, Bensen WG, Conrozier T, Loeuille D, Kivitz AJ, Silver D, Appleton BE. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2009, 61:344-352. 10.1002/art.24096, 19248129.
56. Lange J, Sapozhnikova A, Lu C, Hu D, Li X, Miclau T, Marcucio RS. Action of IL-1beta during fracture healing. J Orthop Res 2010, 28:778-784. 2858256, 20041490.
57. Gerstenfeld LC, Cho TJ, Kon T, Aizawa T, Tsay A, Fitch J, Barnes GL, Graves DT, Einhorn TA. Impaired fracture healing in the absence of TNF-alpha signaling: the role of TNF-alpha in endochondral cartilage resorption. J Bone Miner Res 2003, 18:1584-1592. 10.1359/jbmr.2003.18.9.1584, 12968667.
58. Bostrom MP, Asnis P. Transforming growth factor beta in fracture repair. Clin Orthop Relat Res 1998, 355:S124-S131.
59. Kon T, Cho TJ, Aizawa T, Yamazaki M, Nooh N, Graves D, Gerstenfeld LC, Einhorn TA. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. J Bone Miner Res 2001, 16:1004-1014. 10.1359/jbmr.2001.16.6.1004, 11393777.
60. Fukui N, Zhu Y, Maloney WJ, Clohisy J, Sandell LJ. Stimulation of BMP-2 expression by pro-inflammatory cytokines IL-1 and TNF-alpha in normal and osteoarthritic chondrocytes. J Bone Joint Surg Am Vol 2003, 85-A:59-66.
61. Veitch SW, Findlay SC, Hamer AJ, Blumsohn A, Eastell R, Ingle BM. Changes in bone mass and bone turnover following tibial shaft fracture. Osteoporos Int 2006, 17:364-372. 10.1007/s00198-005-2025-y, 16362144.
62. Cox G, Einhorn TA, Tzioupis C, Giannoudis PV. Bone-turnover markers in fracture healing. J Bone Joint Surg Am 2010, 92:329-334.
63. Matsunaga S, Yamamoto T, Fukumura K. Temporal and spatial expressions of transforming growth factor-betas and their receptors in epiphyseal growth plate. Int J Oncol 1999, 14:1063-1067.
64. Janssens K, ten Dijke P, Janssens S, Van Hul W. Transforming growth factor-beta1 to the bone. Endocr Rev 2005, 26:743-774. 10.1210/er.2004-0001, 15901668.
65. Oursler MJ. Osteoclast synthesis and secretion and activation of latent transforming growth factor beta. J Bone Miner Res 1994, 9:443-452.
66. Robey PG, Young MF, Flanders KC, Roche NS, Kondaiah P, Reddi AH, Termine JD, Sporn MB, Roberts AB. Osteoblasts synthesize and respond to transforming growth factor-type beta (TGF-beta) in vitro. J Cell Biol 1987, 105:457-463. 10.1083/jcb.105.1.457, 2114927, 3475276.
67. Karsdal MA, Henriksen K, Sorensen MG, Gram J, Schaller S, Dziegiel MH, Heegaard AM, Christophersen P, Martin TJ, Christiansen C, Bollerslev J. Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 2005, 166:467-476. 10.1016/S0002-9440(10)62269-9, 1602325, 15681830.
68. Oreffo RO, Mundy GR, Seyedin SM, Bonewald LF. Activation of the bone-derived latent TGF beta complex by isolated osteoclasts. Biochem Biophys Res Commun 1989, 158:817-823. 10.1016/0006-291X(89)92795-2, 2920041.
69. Higuchi H, Shirakura K, Kimura M, Terauchi M, Shinozaki T, Watanabe H, Takagishi K. Changes in biochemical parameters after anterior cruciate ligament injury. Int Orthop 2006, 30:43-47. 10.1007/s00264-005-0023-5, 2254663, 16333657.
70. Giganti MG, Liuni F, Celi M, Gasbarra E, Zenobi R, Tresoldi I, Modesti A, Bei R, Tarantino U. Changes in serum levels of TNF-alpha, IL-6, OPG, RANKL and their correlation with radiographic and clinical assessment in fragility fractures and high energy fractures. J Biol Regul Homeost Agents 2012, 26:671-680.
71. Sui Y, Lee JH, DiMicco MA, Vanderploeg EJ, Blake SM, Hung HH, Plaas AH, James IE, Song XY, Lark MW, Grodzinsky AJ. Mechanical injury potentiates proteoglycan catabolism induced by interleukin-6 with soluble interleukin-6 receptor and tumor necrosis factor alpha in immature bovine and adult human articular cartilage. Arthritis Rheum 2009, 60:2985-2996. 10.1002/art.24857, 19790045.
72. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, Yamaguchi A, Kishimoto T, Suda T, Kashiwazaki S. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996, 11:88-95.
73. Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, Koishihara Y, Ohsugi Y, Kumaki K, Taga T, Kishimoto T, Suda T. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993, 90:11924-11928. 10.1073/pnas.90.24.11924, 48097, 8265649.
74. Di Cesare PE, Fang C, Leslie MP, Tulli H, Perris R, Carlson CS. Expression of cartilage oligomeric matrix protein (COMP) by embryonic and adult osteoblasts. J Orthop Res 2000, 18:713-720. 10.1002/jor.1100180506, 11117291.
75. DiCesare P, Hauser N, Lehman D, Pasumarti S, Paulsson M. Cartilage oligomeric matrix protein (COMP) is an abundant component of tendon. FEBS Lett 1994, 354:237-240. 10.1016/0014-5793(94)01134-6, 7957930.
76. Saxne T, Heinegard D. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol 1992, 31:583-591. 10.1093/rheumatology/31.9.583, 1381980.
77. Vilim V, Vytasek R, Olejarova M, Machacek S, Gatterova J, Prochazka B, Kraus VB, Pavelka K. Serum cartilage oligomeric matrix protein reflects the presence of clinically diagnosed synovitis in patients with knee osteoarthritis. Osteoarthritis Cartilage 2001, 9:612-618. 10.1053/joca.2001.0434, 11597173.
78. Smith RK, Heinegard D. Cartilage oligomeric matrix protein (COMP) levels in digital sheath synovial fluid and serum with tendon injury. Equine Vet J 2000, 32:52-58. 10.2746/042516400777612053, 10661386.